The p.D202N mutation in PRNP is a rare variant associated with Gerstmann-Sträussler-Scheinker disease (GSS), a genetic form of prion cerebral amyloidosis. To date, there have been only 4 reports of this mutation worldwide and only one detailed clinical study (table e-1, links. lww.com/NXG/A223). 1-4 Here, we describe the clinical phenotype and the results of neuroradiologic and laboratory investigations in an Italian patient carrying this genetic variant.
Discussion
GSS is a genetic prion disease caused by several point (i.e., missense, nonsense) or insertional mutations in PRNP. 5 The clinical phenotype of GSS is heterogeneous and may include ataxia, spastic paraparesis, cognitive decline, and amyotrophy as presenting signs. Parkinsonism may also occur, 5 but not as the dominant clinical feature, especially at disease onset. As the most significant exception, patients with GSS carrying the p.D202N substitution consistently showed early extrapyramidal features, often raising the suspicion of atypical parkinsonian syndrome. Notably, family history was strongly positive for parkinsonism in one case (i.e., overall 9 subjects in 5 generations), with the proband's mother and cousin being diagnosed with progressive supranuclear palsy. 2, 4 In line with these observations, 123 I-ioflupane SPECT (DaTscan) gave abnormal results in both patients who underwent this test (table e-1, links.lww.com/NXG/A223). In our patient, parkinsonism was not either dominant or isolated at disease onset, but the concurrence of parkinsonism with ataxia and pyramidal signs raised the suspicion of MSA, which belongs to the spectrum of atypical parkinsonisms.
The causative role of the p.D202N mutation in our patient is supported by the similar presentation among reported cases. [2] [3] [4] and the neuropathologic studies documenting a genuine GSS phenotype in 3 previously described cases carrying the p.D202N mutation examined neuropathologically, a phenotype which has never been reported to date in a subject carrying the wild-type PRNP sequence. 1-3 However, given the absence of a positive family history in the present case (as well in others), 4 we cannot definitely rule out the possibility of an incomplete penetrance of the p.D202N variant.
It is well established that the methionine (M)/valine(V) polymorphism at PRNP codon 129 strongly modulates the disease phenotype of human prion disease. 6 In GSS-p.D202N, the mutation cosegregated with V129. Indeed, valine homozygosity at codon 129 was documented in 3 patients, and the mutation was in cis with valine in a fourth case (table e-1, links. lww.com/NXG/A223).
Of interest, the CSF profile in our cases indicated a severe neurodegenerative process associated with the accumulation of phosphorylated tau protein, without a concomitant A-Beta protein deposition. 7 This finding is also in line with the diagnosis of GSS, given that the secondary tau-positive neurofibrillary pathology is a neuropathologic hallmark of GSS 5,e1 and also occurred in the 3 previously described cases carrying the p.D202N variant. [1] [2] [3] Finally, the negative CSF prion RT-QuIC result is not surprising because, despite the few cases analyzed, the suboptimal diagnostic accuracy of this assay for GSS has been already reported by different groups. e2-e4 Our and previous observations underline the importance of considering the GSS-p.D202N-V129 variant in the differential diagnosis of patients with atypical parkinsonism, especially when associated with cerebellar and/or pyramidal signs and dementia.
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